ABL Bio Inc. (KOSDAQ:298380)
South Korea · Delayed Price · Currency is KRW 71,000
-1,700 (-2.34%)
Sep 1, 2026, 3:30 PM KST
ABL Bio Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 34,283 | 79,350 | 33,403 | 65,547 | 67,301 | 5,332 |
Revenue Growth | -63.89% | 137.55% | -49.04% | -2.61% | 1162.19% | - |
Gross Profit Gross Profit Growth | 34,168 | 79,229 | 33,342 | 65,501 | 67,217 | 5,284 |
Operating Income Operating Income Growth | -86,119 | -40,390 | -59,377 | -2,617 | 908 | -51,188 |
Net Income Net Income Growth | -78,631 | -37,806 | -55,529 | -2,647 | 3,209 | -43,558 |
Earnings Per Share EPS Growth | -1424.72 | -734.08 | -1156.34 | -55.32 | 67.46 | -927.36 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
South Korea South Korea Growth | 400 | 300 | 1,996 | 2,384 | 483.55 |
United States United States Growth | 5,773 | 33,103 | 63,551 | 62,315 | 4,849 |
UK UK Growth | 73,177 | - | - | - | - |
Total Total Growth | 79,350 | 33,403 | 65,547 | 67,301 | 5,332 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 167,083 | 114,945 | 141,512 | 71,165 | 78,317 | 43,721 |
Total Debt Total Debt Growth | 55,449 | 55,327 | 43,663 | 43,938 | 41,836 | 574.35 |
Net Cash (Debt) Net Cash Growth | 111,635 | 59,618 | 97,849 | 27,227 | 36,481 | 43,147 |
Net Cash Growth | 18.16% | -39.07% | 259.38% | -25.37% | -15.45% | - |
Net Cash Per Share Net Cash Per Share Growth | 2022.71 | 1157.60 | 2037.61 | 569.08 | 766.95 | 918.60 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -41,760 | -41,253 | -69,403 | -28,362 | 72,132 | -40,605 |
Capital Expenditures CapEx Growth | -5,322 | -20,065 | -9,023 | -5,740 | -2,055 | -1,244 |
Free Cash Flow Free Cash Flow Growth | -47,083 | -61,318 | -78,426 | -34,102 | 70,076 | -41,850 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 99.67% | 99.85% | 99.82% | 99.93% | 99.88% | 99.10% |
Operating Margin | -251.20% | -50.90% | -177.76% | -3.99% | 1.35% | -959.99% |
Pretax Margin | -230.93% | -47.73% | -166.24% | -4.04% | 4.77% | -816.91% |
Profit Margin | -229.36% | -47.64% | -166.24% | -4.04% | 4.77% | -816.91% |
FCF Margin | -137.34% | -77.28% | -234.79% | -52.03% | 104.12% | -784.87% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 342.55 | - |
Forward PE | 15900.44 | 277.59 | - | - | - | - |
P/FCF Ratio | - | - | - | - | 15.69 | - |
PS Ratio | 115.95 | 138.94 | 43.22 | 17.97 | 16.33 | 195.31 |